Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Long-Term Investments for 5 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 4.51% year-over-year to $22.5 million, compared with a TTM value of $22.5 million through Dec 2025, up 4.51%, and an annual FY2025 reading of $22.5 million, up 4.51% over the prior year.
  • Long-Term Investments was $22.5 million for Q4 2025 at Catalyst Pharmaceuticals, up from $19.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $24.2 million in Q1 2025 and bottomed at $12.9 million in Q3 2023.
  • Average Long-Term Investments over 3 years is $18.4 million, with a median of $19.2 million recorded in 2025.
  • Peak annual rise in Long-Term Investments hit 62.47% in 2025, while the deepest fall reached 4.51% in 2025.
  • Year by year, Long-Term Investments stood at $16.5 million in 2023, then soared by 30.78% to $21.6 million in 2024, then grew by 4.51% to $22.5 million in 2025.
  • Business Quant data shows Long-Term Investments for CPRX at $22.5 million in Q4 2025, $19.2 million in Q3 2025, and $21.3 million in Q2 2025.